Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the engagement with a group of distinguished scientific advisors who will provide strategic input as Legend advances its pipeline and future research priorities.

GlobeNewsWire • May 4, 2026

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results.

GlobeNewsWire • Apr 28, 2026

Legend Biotech: Undervalued Leader In The CAR-T Race

In my opinion, Legend Biotech Corporation is an attractive acquisition target for Johnson & Johnson. Carvykti, which they are jointly developing, is quickly catching up in sales with Darzalex, J&J's blockbuster for the treatment of multiple myeloma. So, sales of Carvykti reached $597 million in Q1, up 61.8% year-on-year, beating my 'best case' scenario by $15 million.

Seeking Alpha • Apr 24, 2026

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Apr 21, 2026

Why Legend Biotech Stock Crushed the Market on Monday

This followed a sizable acquisition of a peer biotech by a pharmaceutical sector giant. Legend has innovative science backing its oncology drug development efforts.

The Motley Fool • Apr 20, 2026

Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript

Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 10, 2026

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2025, and key corporate highlights.

GlobeNewsWire • Mar 10, 2026

Artisan International Small-Mid Fund Q4 2025 Performance Review

The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Our portfolio, which has a structural growth orientation, has no exposure to these cyclical, capital-intensive and highly regulated market segments. On an individual company basis, Metso, Celcuity and LivaNova were the largest Q4 contributors.

Seeking Alpha • Mar 2, 2026

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results.

GlobeNewsWire • Feb 24, 2026

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.

Seeking Alpha • Jan 30, 2026